ScoreWhy is Yifan Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 2.72%
- The company has been able to generate a Return on Capital Employed (avg) of 2.72% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of -1.22% and Operating profit at -22.96% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 3.20% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of -1.22% and Operating profit at -22.96% over the last 5 years
4
The company has declared Positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY 786.16 MM
- ROCE(HY) Highest at 5.05%
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
5
With ROE of 4.51%, it has a fair valuation with a 1.35 Price to Book Value
- Over the past year, while the stock has generated a return of 1.86%, its profits have risen by 152.2% ; the PEG ratio of the company is 0.2
- At the current price, the company has a high dividend yield of 0.8
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Yifan Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Yifan Pharmaceutical Co., Ltd. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Yifan Pharmaceutical Co., Ltd.
6.56%
0.03
33.14%
China Shanghai Composite
14.77%
1.01
15.10%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-1.22%
EBIT Growth (5y)
-22.96%
EBIT to Interest (avg)
1.55
Debt to EBITDA (avg)
2.27
Net Debt to Equity (avg)
0.15
Sales to Capital Employed (avg)
0.42
Tax Ratio
10.01%
Dividend Payout Ratio
63.03%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.72%
ROE (avg)
3.20%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
30
Industry P/E
Price to Book Value
1.35
EV to EBIT
36.09
EV to EBITDA
18.26
EV to Capital Employed
1.30
EV to Sales
2.61
PEG Ratio
0.20
Dividend Yield
0.82%
ROCE (Latest)
3.61%
ROE (Latest)
4.51%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend32What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 786.16 MM
ROCE(HY)
Highest at 5.05%
INTEREST COVERAGE RATIO(Q)
The company hardly has any interest cost
RAW MATERIAL COST(Y)
Fallen by -6.74% (YoY
NET PROFIT(9M)
Higher at CNY 323.6 MM
OPERATING PROFIT(Q)
Highest at CNY 281.69 MM
OPERATING PROFIT MARGIN(Q)
Highest at 21.7 %
PRE-TAX PROFIT(Q)
At CNY 195.48 MM has Grown at 85.84%
-8What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at 17.21 %
CASH AND EQV(HY)
Lowest at CNY 1,660.2 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 2.86%
Here's what is working for Yifan Pharmaceutical Co., Ltd.
Net Profit
At CNY 323.6 MM has Grown at 172.77%
Year on Year (YoY)MOJO Watch
Net Profit trend is very positive
Net Profit (CNY MM)
Net Profit
At CNY 323.6 MM has Grown at 172.77%
Year on Year (YoY)MOJO Watch
Net Profit trend is very positive
Net Profit (CNY MM)
Operating Cash Flow
Highest at CNY 786.16 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Operating Cash Flow
Highest at CNY 786.16 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Operating Profit
Highest at CNY 281.69 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit
Highest at CNY 281.69 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 21.7 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Operating Profit Margin
Highest at 21.7 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY 195.48 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Pre-Tax Profit
Highest at CNY 195.48 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Pre-Tax Profit
At CNY 195.48 MM has Grown at 85.84%
over average net sales of the previous four periods of CNY 105.19 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Pre-Tax Profit
At CNY 195.48 MM has Grown at 85.84%
over average net sales of the previous four periods of CNY 105.19 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Higher at CNY 323.6 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Profit (CNY MM)
Net Profit
Higher at CNY 323.6 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Profit (CNY MM)
Raw Material Cost
Fallen by -6.74% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Raw Material Cost
Fallen by -6.74% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Yifan Pharmaceutical Co., Ltd.
Debt-Equity Ratio
Highest at 17.21 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Debt-Equity Ratio
Highest at 17.21 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Cash and Eqv
Lowest at CNY 1,660.2 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Cash and Eqv
Lowest at CNY 1,660.2 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio
Lowest at 2.86%
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Debtors Turnover Ratio
Lowest at 2.86%
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
